Sorrento Therapeutics Inc. (SRNE): Wildcat Capital Management Ups Its Stake and Reiterates Demands

Page 3 of 15

Page 3 of 15 – SEC Filing
CUSIP No. 83587F202 13D Page 3 of 15 Pages
1

NAMES OF REPORTING PERSONS

Wildcat – Liquid Alpha, LLC

2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(see instructions)

(a)

(b)

3  SEC USE ONLY
4

SOURCE OF FUNDS(see instructions)

WC (See Item 3)

5 CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)
6

CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

NUMBER OF SHARES

BENEFICIALLY OWNED BY
EACH REPORTING

PERSON WITH

7

SOLE VOTING POWER

-0-

8

SHARED VOTING POWER

184,000 (See Items 3, 4 and 5)

9

SOLE DISPOSITIVE POWER

-0-

10

SHARED DISPOSITIVE POWER

184,000 (See Items 3, 4 and 5)

11

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING
PERSON

184,000 (See Items 3, 4 and 5)

12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)
13

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11

0.5% (See Item 5)*

14

TYPE OF REPORTING PERSON

OO

* The calculation assumes that there are a total of 40,212,795 shares of Common Stock outstanding as of May 3, 2016, as set forth
in the Issuer’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2016, filed with the SEC on May 10, 2016.

Follow Sorrento Therapeutics Inc. (NASDAQ:SRNEQ)

Page 3 of 15